CORE--ADHERENCE CORE

坚持核心是支持三项干预的共享资源 包含行为成分的研究。粉碎资源的目标是： 1)促进参与者遵守/遵守Fibre、Piroxicam和DFMO 试验，2)咨询并提供适用于 其他核心，3)将健康行为配置文件的敏感性记录在 区分好的、边缘的和贫穷的追随者，使必要的 改进，以及4)确定与短期和长期相关的因素 坚持三大防癌方略的成败 并对有结肠癌风险的参与者进行对照试验，以确定 IV期试验中低依从性的潜在易感因素，5) 确定基于健康行为档案的坚持的有效性 干预。纤维组织受试者(n=1000)、吡罗昔康(n=100)和DFMO受试者 (n=100)试验对象为有腺瘤性息肉病史的40-80岁的老年人。 主要使用相关数据。此外，一个预期的病例对照 具有与好的匹配的穷人和边缘追随者的子样本的策略 使用附着者对照(n=81)来评估目标4。描述性统计， 哈维-戈尔茨坦ML-2对目标4的分析和基于经济的效率 将执行AIM#5的分析。核心成果包括坚持 促进--基于健康行为档案的效率评估 干预，检验一般性和个别化的有效性 干预措施，并对导致粘连失败的因素进行描述 以社区为基础的第四阶段癌症预防和控制的准备工作 针对结肠癌高危人群的试验。

Adherence Core is a shared resource which supports the three intervention studies with behavioral components. The aims of the shred resource are: 1) Promote participant adherence/compliance with fiber, piroxicam and DFMO trials, 2) Consult with and provide behavioral findings applicable to other Cores, 3) document the Health Behavior Profile for sensitivity in distinguishing among good, marginal and poor adherers, making necessary refinements, and 4) Identify factors associated with short and long-term adherence success and failure in the three representative cancer prevention and control trials with participants at risk for colon cancer, to identify potential predisposing factors for low adherence in Phase IV trials, 5) Identify the efficacy of the Health Behavior Profile-based adherence intervention. Subjects in the fiber (n 1000), piroxicam (n=100) and DFMO (n=100) trials are 40-80 year olds with a history of adenomatous polyps. Primarily correlational data are used. Also, a prospective case control strategy with a subsample of poor and marginal adherers matched with good adherer controls (n=81) is used to assess aim #4. Descriptive statistics, Harvey-Goldstein ML-2 analysis for aim #4 and an economic-based efficiency analysis for aim #5 will be performed. Core outcomes include adherence promotion, an efficiency estimate of the Health Behavior Profile-based intervention, a test of the effectiveness of the general and individualized interventions, and description of factors in adherence failure in preparation for Phase IV cancer prevention and control community-based trials with people at risk for colon cancer.